Image Ben Hargreaves Patients Action by FDA ensures trial sponsors must consider diversity Pharma has recognised that there is a problem with diversity in clinical trials, but has so far struggled to successfully achieve real change. Market Access How the pandemic exposed faulty links in the supply chain The pandemic provided a harsh shock to healthcare, but proved particularly tough on the supply chains relied on to support public health. Patients Healthcare report finds declining public trust in institutio... There are few things more important than health, but a recent report suggests that the public has declining trust in traditional healthcare institutions to protect theirs. Market Access Is the UK’s healthcare spending drop sustainable? The UK’s health system has been under pressure to manage costs whilst still delivering a reliable service. Load more results
Patients Action by FDA ensures trial sponsors must consider diversity Pharma has recognised that there is a problem with diversity in clinical trials, but has so far struggled to successfully achieve real change.
Market Access How the pandemic exposed faulty links in the supply chain The pandemic provided a harsh shock to healthcare, but proved particularly tough on the supply chains relied on to support public health.
Patients Healthcare report finds declining public trust in institutio... There are few things more important than health, but a recent report suggests that the public has declining trust in traditional healthcare institutions to protect theirs.
Market Access Is the UK’s healthcare spending drop sustainable? The UK’s health system has been under pressure to manage costs whilst still delivering a reliable service.
News NHS to offer Wegovy to a million more people in England The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
